Literature DB >> 15377799

Clinical and familial correlates of tardive dyskinesia in India and Israel.

T Bhatia1, M R Sabeeha, V Shriharsh, K Garg, R H Segman, H L Uriel, R Strous, V L Nimgaonkar, L Bernard, S N Deshpande.   

Abstract

BACKGROUND: Antipsychotic drugs are widely used for the treatment of psychosis, especially schizophrenia. Their long-term use can result at times in serious side-effects such as Tardive Dyskinesia (TD). Since over 80% of schizophrenia sufferers (lifetime prevalence 1%) receive long-term antipsychotic drug treatment, the extent of the problem is potentially large. Increasing age is the most consistently demonstrated risk factor for TD. AIMS: To assess effect of different clinical factors and demographic variables in India and Israel and sib pair concordance of Tardive Dyskinesia (TD) in India. SETTINGS AND
DESIGN: The study was conducted simultaneously among Indian and Israeli subjects: ascertainment was family-based in India and hospital-based in Israel. METHODS AND MATERIAL: In India the instruments used were: Diagnostic Interview for Genetic Studies (DIGS), Positive and Negative Syndrome Scale (PANSS), Abnormal Involuntary Movement Scale (AIMS), and Simpson Angus Scale (SAS). The last three instruments were also used in Israel. STATISTICAL ANALYSIS: Regression analysis and Pearson's correlation. RESULTS AND
CONCLUSIONS: TD symptoms were present in 40.4% of 151 Israeli subjects and 28.7% of 334 Indian subjects. While age at onset and total scores on PANSS were significant predictors of TD in both the samples, lower scores on the Global Assessment of Functioning Scale (GAF), diagnostic sub-group and male gender were significant predictors among Indians. There was no concordance of TD symptoms among 33 affected sib-pairs from India.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377799

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  3 in total

1.  An examination of patient-identified goals for treatment in a first-episode programme in Chennai, India.

Authors:  Srividya N Iyer; Ramamurti Mangala; Jeyagurunathan Anitha; Rangaswamy Thara; Ashok K Malla
Journal:  Early Interv Psychiatry       Date:  2011-09-27       Impact factor: 2.732

Review 2.  Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis.

Authors:  Sara Ormerod; Sarah E McDowell; Jamie J Coleman; Robin E Ferner
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Prevalence of spontaneous dyskinesia in first episode, drug naive schizophrenia, and its relation to the positive and negative symptoms of schizophrenia.

Authors:  Samrat Singh Bhandari; Dipesh Bhagabati
Journal:  Open J Psychiatry Allied Sci       Date:  2016-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.